Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)

This study is currently recruiting participants.
Verified March 2011 by Clinical Evaluation Research Unit at Kingston General Hospital
Sponsor:
Collaborator:
Baxter Healthcare Corporation
Information provided by:
Clinical Evaluation Research Unit at Kingston General Hospital
ClinicalTrials.gov Identifier:
NCT01206166
First received: September 14, 2010
Last updated: June 23, 2011
Last verified: March 2011
  Purpose

The specific aim of the proposed study is to conduct a pilot study involving 160 critically-ill lean and obese patients enrolled at 9 sites in Canada, the United States of America, Belgium and France in order to:

Specific Aims

  • Confirm that we can achieve a clinically significant difference in calorie and protein intake between the two intervention groups.
  • Estimate recruitment rate i.e. number of eligible and enrolled patients per month per site.
  • Evaluate the safety, tolerance, and logistics around providing supplemental PN in the study population in the context of a multicenter trial, e.g.

    • To ensure adequate glycemic control in both groups.
    • To ensure that the other metabolic consequences of the feeding strategies are minimized.
    • To establish adequate compliance with study protocols and completion of case report forms

A secondary aim of this pilot study will be:

• To explore the effect of differential effects of calorie and protein delivery on muscle and mass function.


Condition Intervention Phase
Critical Illness
Acute Respiratory Failure
Dietary Supplement: Olimel (5.7%E / N9E)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)

Resource links provided by NLM:


Further study details as provided by Clinical Evaluation Research Unit at Kingston General Hospital:

Primary Outcome Measures:
  • Amount of calories and protein received [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  • 60 day mortality [ Time Frame: 60 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • ICU mortality [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  • Development of ICU-acquired infections [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  • Hospital mortality [ Time Frame: 60 days ] [ Designated as safety issue: No ]
  • Duration of ICU stay [ Time Frame: 60 days ] [ Designated as safety issue: No ]
  • Multiple organ dysfunction (SOFA and PODS) [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Sequential Organ Failure Assessment(SOFA) Persistant Organ Dysfuntion Score (PODS)

  • Duration of mechanical ventilation. [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  • SF36 [ Time Frame: 60 days ] [ Designated as safety issue: No ]
    Survival and health-related quality of life

  • Duration of hospital stay [ Time Frame: 60 days ] [ Designated as safety issue: No ]
  • Muscle Function - Ultrasounds [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Ultrasounds of the femoral quadricepe will be done to assess the muscle layer thickness (MLT) of the M. vastus intermedius and M rectus femoris.

  • Muscle Function - CT Scans [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    CT scans done for clinical reasons done at the 3rd lumbar vertebrae will be used to assess muscle mass.

  • Muscle Function - Hand-Grip Strength [ Time Frame: ICU Discharge ] [ Designated as safety issue: No ]
    At ICU discharge, a hand-grip strength test will be done.

  • Muscle Function - 6 min walk test [ Time Frame: ICU Discharge ] [ Designated as safety issue: No ]
    At ICU discharge, a 6 min walk test will be done.


Estimated Enrollment: 160
Study Start Date: June 2011
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Enteral Nutrition plus Parenteral Nutrition
Enteral nutrition with the addition of parenteral supplementation (Olimel 5.7%E/N9E).
Dietary Supplement: Olimel (5.7%E / N9E)
OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
No Intervention: Enteral Nutrition Only

Detailed Description:

Background

Critically ill patients are often hypermetabolic and can rapidly become nutritionally compromised. Malnutrition is prevalent in these patients and has been associated with increased morbidity and mortality. Standard nutrition therapy, i.e. provision of calories, protein and other nutrients consists primarily of enteral nutrition (via a feeding tube into the gastrointestinal tract), parenteral nutrition (via an intravenous tube into the blood), or occasionally a combination of both.

However, the provision of nutrition is sub-optimal and the majority of critically-ill patients do not meet nutritional requirements. Recent studies report that average energy intakes of critically ill patients are only 49% to 70% of calculated requirements. Despite repeated, sustained efforts over the past few years, the investigators have not significantly improved the amount of calories delivered via the enteral route. This leads us to conclude that if the investigators are to be successful at increasing the provision of calories and protein to patients at-risk, the investigators will have to supplement the calories via the parenteral route.

Critically ill patients that are at extremes of weight are at a higher nutritional risk and have higher mortality rates. A recent International multicenter observational study of 2772 ICU patients from 165 ICUs showed a significant inverse linear relationship between the odds of mortality and total daily calories received. Increased amounts of calories was most important for the BMI < 20 group followed by the BMI 20 -< 25 group and BMI > 35 group with no benefit of increased calorie intake for patients in the BMI 25 -< 35 group. Feeding an additional 1000 kcals almost halved the odds of 60-day mortality in patients with a BMI < 25 or > 35. Similar results were observed for feeding an additional 30 grams of protein per day.

Thus, a prospective randomized trial is warranted to confirm our hypothesis that in patients with a BMI of < 25 and those with a BMI > 35 increasing the provision of more energy and protein can impact clinical outcomes. The results of this study will serve to answer some fundamental questions with regards to impact of amount of energy and protein delivered to nutritional at-risk ICU patients and will inform current practice.

Study Intervention:

Patients will be randomized to one of 2 interventions: enteral nutrition alone or enteral nutrition plus parenteral nutrition (supplemental PN group).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Mechanically ventilated adult patients (≥18 years old) admitted to the ICU
  • On or are expected to initiate enteral nutrition within 48 hours from ICU admission
  • Are expected to remain mechanically ventilated for more than 72 hours
  • Have a BMI < 25 or >35, based on pre-ICU actual or estimated dry weight

Exclusion Criteria:

  • >48 hrs from ICU admission to consent
  • Not expected to survive an additional 48 hours from screening evaluation
  • Lack of commitment to full, aggressive care (anticipated withholding or - withdrawing treatments in the first week but isolated DNR acceptable)
  • Patients with an absolute contraindication to EN deemed to require PN for the first 7 days of ICU admission (e.g., GI obstruction or no GI tract access for any reason)
  • Already at goal rate of enteral nutrition from screening evaluation (receiving ≥ 60% estimated needs and no evidence of intolerance i.e. high gastric residual volumes, etc)
  • Patients already receiving PN on admission to ICU
  • Patients admitted with Diabetic Ketoacidosis or non-ketotic hyperosmolar coma
  • Pregnant or lactating patients
  • Patients with clinical fulminant hepatic failure
  • Dedicated port of central line not available
  • Known allergy to study nutrients and
  • Enrolment in another industry sponsored ICU intervention study (co-enrollment in academic studies will be considered on a case by case basis)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01206166

Contacts
Contact: Rupinder Dhaliwal 613-549-6666 ext 3830 dhaliwar@kgh.kari.net

Locations
United States, Colorado
University of Colorado DHSC Not yet recruiting
Boulder, Colorado, United States, 80045
Contact: Paul Wischmeyer, MD         Paul.Wischmeyer@ucdenver.edu    
United States, Oregon
Oregon Health & Science University Not yet recruiting
Portland, Oregon, United States, 97239-3098
Contact: Bob Martindale         martindr@ohsu.edu    
United States, Vermont
University of Vermont Not yet recruiting
Burlington, Vermont, United States, 05401
Contact: Renee Stapleton         renee.stapleton@uvm.edu    
United States, Wisconsin
University of Wisconsin Not yet recruiting
Madison, Wisconsin, United States, 53705
Contact: Ken Kudsk         kudsk@surgery.wisc.edu    
Belgium
Erasme University Hospital Not yet recruiting
Brussels, Belgium, B - 1070
Contact: Jean-Charles Preiser, MD         Jean-Charles.Preiser@erasme.ulb.ac.be    
Canada, Alberta
Royal Alexandra Hospital Recruiting
Edmonton, Alberta, Canada, T5H 3V9
Contact: Jim Kutsogiannis, MD         jim.kutsogiannis@ualberta.ca    
University of Alberta Not yet recruiting
Edmonton, Alberta, Canada, T5H 3V9
Contact: Constantine D Karvellas, MD         dean.karvellas@ualberta.ca    
Grey Nuns Hospital Not yet recruiting
Edmonton, Alberta, Canada, T6L 5X8
Contact: Dan Stollery         dstoller@ualberta.ca    
France
Nouvel Hôpital Civil Not yet recruiting
Strasbourg, France, F - 67091
Contact: Michel Hasselmann, MD         michel.hasselmann@chru-strasbourg.fr    
Sponsors and Collaborators
Clinical Evaluation Research Unit at Kingston General Hospital
Baxter Healthcare Corporation
Investigators
Study Chair: Daren K. Heyland, MD Clinical Evaluation Research Unit, Kingston General Hospital
  More Information

Additional Information:
Publications:
Responsible Party: Dr. D. Heyland, Kingston General Hospital
ClinicalTrials.gov Identifier: NCT01206166     History of Changes
Other Study ID Numbers: TOP-UP
Study First Received: September 14, 2010
Last Updated: June 23, 2011
Health Authority: Canada: Health Canada
United States: Food and Drug Administration
Belgium: Federal Agency for Medicinal Products and Health Products
France: Direction Générale de la Santé

Keywords provided by Clinical Evaluation Research Unit at Kingston General Hospital:
Randomized trial
Parental nutrition
Enteral nutrition
Intensive care unit
BMI < 25 or ≥ 35

Additional relevant MeSH terms:
Critical Illness
Respiratory Distress Syndrome, Adult
Respiratory Insufficiency
Overweight
Disease Attributes
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on June 18, 2013